CIBRA Capital Acquires 1.48M Shares of Amicus Therapeutics (FOLD)

CIBRA Capital Ltd increased its shareholding in Amicus Therapeutics (FOLD) by 1,476,861 shares, valued at approximately $21.17 million as per the SEC filing on April 24, 2026. The total value of this position rose to $24.40 million, accounting for 11.78% of CIBRA's reportable assets under management. This transaction reflects a 10.2% increase in assets and comes as Amicus shares were priced at $14.46, having achieved a 103.7% total return over the past year. Key products include therapies for rare diseases like Fabry and Pompe, contributing to $634.21 million in revenue.